Alnylam Pharmaceuticals, Inc. Earnings

Alnylam Pharmaceuticals, Inc.’s revenue fell -33.26% since last year same period to $500.92Mn in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -24.08% fall in its revenue since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit fell -175.51% since last year same period to $-111.57Mn in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -560.61% fall in its net profits since last 3-months.

Alnylam Pharmaceuticals, Inc.’s net profit margin fell -213.14% since last year same period to -22.27% in the Q3 2024. On a quarterly growth basis, Alnylam Pharmaceuticals, Inc. has generated -770.17% fall in its net profit margins since last 3-months.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.93 - a 13.89% jump from last quarter’s estimates.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -0.93.

Alnylam Pharmaceuticals, Inc.’s earning per share (EPS) fell -175.65% since last year same period to -0.87 in the Q3 2024. This indicates that the Alnylam Pharmaceuticals, Inc. has generated -175.65% annual rate of fall in its earning per share (EPS) in the last 4 quarters.